The study not only contributes to our understanding of the molecular mechanisms underlying T2D-associated neurodegeneration but also positions Cdk5 inhibition as a compelling strategy for mitigating the complex interplay between metabolic disorders and cognitive decline. Here, CDK5 is linked to metabolic disease.